Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Global Medtech Guidance Tracker: February 2022

Executive Summary

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-six documents have been posted on the tracker since its last update.

You may also be interested in...



Malaysia Consults On Medical Device Risk Classifications

A 20-day consultation on the risk classification of medical devices intended for the Malaysia market ends on 28 February

Guidance Sets Out How Notified Bodies Must Assess Highest Risk IVDs Under New Regulation

The highest risk IVDs, which fall into class D, are subject to additional testing criteria. New guidance explains how the notified body acts not only as reviewer but also as facilitator so additional safety and performance guarantees can be sought.

Global Medtech Guidance Tracker: September 2022

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Forty-two documents have been posted on the tracker since its last update.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT145139

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel